Glimsay M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The prolonged-release formulation ensures a gradual release of active ingredients, promoting sustained plasma concentrations and improved patient compliance. Glimsay M2 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent are insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly to minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. This medication should be used under strict medical supervision, with periodic assessment of renal function and glycemic status to optimize therapeutic outcomes and minimize potential risks.